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Background: Diagnostic imaging guidelines are increasingly embraced in oncologic 
imaging in order to improve examinations appropriateness and technical quality. The 
usefulness of guidelines employment in clinical practice is dramatically related to the 
quality of the guidelines themselves. However, an extreme variability in guidelines’ 
quality may occur. Following a European Network for the Assessment of Imaging in 
Medicine (EuroAIM) initiative, the aim of this study was to assess the quality of the 
available guidelines regarding head and neck cancer (HNC) imaging.
Methods: A literature search was conducted to identify imaging guidelines focused 
on HNC. Selected guidelines were evaluated by four independent appraisers using 
the Appraisal of Guidelines for Research & Evaluation version 2.0 (AGREE II) tool, 
which comprises 23 key items, rated on a 7‐point scale (1—strongly disagree to 7—
strongly agree) and organized within six domains. For each domain, the intraclass 
correlation coefficient (ICC) was used to assess the agreement among appraisers’ 
scores.
Results: After literature search, three guidelines were selected and evaluated. One 
guideline scored “average” as overall quality, while the remaining two scored a 
“low” overall quality. The highest result (total score = 75.0% ± 19.3%) was obtained 
in domain 4 (Clarity of presentation) while the lowest (total score = 27.1% ± 4.2%) 
in domain 6 (Editorial independence). ICC analysis showed a very good agreement 
(range: 0.932‐0.961) among the four appraisers.
Conclusions: Our results showed a heterogeneous quality of existing guidelines in 
HNC imaging. Issues raised from this appraisal should be considered when develop-
ing future guidelines on HNC imaging.
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1 |  INTRODUCTION
Head and neck cancer (HNC) includes a broad spectrum of 
malignancies, anatomically related but different in terms of 
management, accounting for about 4% of cancer incidence 
in Europe.1 Imaging plays a crucial role in the diagnos-
tic evaluation of patients affected by HNC, being able to 
add pivotal information related to diagnosis, staging, and 
response to therapy, significantly contributing to improve 
HNC prognosis.2-4 Advanced cross‐sectional imaging mo-
dalities enable radiologists to assess disease extent, its 
spread to neighboring structures and local lymph nodes, 
perineural or perivascular spread, and bone invasion, as 
well as to identify distant metastases and the presence 
of relevant comorbidities. Imaging is also used to guide 
biopsies, for treatment planning (radiotherapy and com-
puter‐assisted surgery), and patient restaging after therapy, 
while detecting persistent or recurrent disease; moreover, it 
has been proved to increase the diagnostic yield in the un-
known head and neck primary population, allowing a more 
targeted treatment.5
Therefore, an appropriate use of the available imaging 
techniques appears of paramount importance to achieve the 
best outcome for patients. For this reason, diagnostic im-
aging guidelines for physicians and radiologists have been 
released with the aim of improving appropriateness and tech-
nical quality of imaging examinations.6-10 While guidelines 
are increasingly embraced in oncologic imaging, concerns 
have been raised about their reliability since their quality can 
be remarkably variable, which dictates their methodological 
evaluation11,12 and may potentially affect guideline useful-
ness and benefits.
Among various quality appraisal instruments developed 
for evaluating guidelines quality in terms of methodolog-
ical rigor and transparency,13 the Appraisal of Guidelines 
for Research & Evaluation version 2.0 (AGREE II) has been 
validated and proved to be a reliable tool14 being already 
applied for clinical practice guidelines in different fields, 
including HNC.15-19 In this setting, the European Network 
for the Assessment of Imaging in Medicine (EuroAIM) was 
founded by the European Institute for Biomedical Imaging 
Research (EIBIR)20 with the purpose of seeking evidence 
for the best use of radiological technology. Recently, 
EuroAIM has focused its activity on the evaluation of the 
quality of guidelines in different fields of diagnostic im-
aging.21,22 Considering the well‐conducted previous expe-
riences focused on specific organs belonging to the head 
and neck area (eg, thyroid cancer),17,19 we decided to em-
brace a wider approach focusing our analysis on guidelines 
dealing with head and neck in a more comprehensive view. 
Therefore, the aim of this study was to evaluate the quality 
of current guidelines on imaging of HNC using the AGREE 
II quality assessment tool.
2 |  MATERIALS AND METHODS
2.1 | Literature search and guidelines 
selection
Between March and April 2018, a literature search was 
conducted on PubMed, EMBASE, Web of Science, 
Scopus, Wiley Online Library, and Google to identify im-
aging guidelines focused on HNC, using the following key-
words: “head and neck cancer imaging,” “head and neck 
neoplasms,” “guidelines,” “recommendations,” “official 
positions,” and their expansions. The reference section of 
the retrieved papers was also checked in order to seek fur-
ther articles to include. Inclusion criteria were the follow-
ing: (a) guidelines focused on HNC imaging; (b) guidelines 
concerning adult population; and (c) guidelines with avail-
able English full text. Exclusion criteria were as follows: 
(a) guidelines not exclusively or primarily focused on HNC 
imaging (eg, clinical practice guidelines in which imaging 
is described in a wider context); (b) guidelines not devel-
oped by recognized institutions/groups of affiliated gov-
ernmental organizations; and (c) guidelines not including 
all major imaging techniques (ie, ultrasound, computed to-
mography, magnetic resonance imaging, positron emission 
tomography). In case of disagreement among the apprais-
ers during the screening process, inclusion and exclusion 
criteria were evaluated and applied in consensus.
2.2 | AGREE II tool
Guidelines were evaluated using the AGREE II tool, which 
comprises twenty‐three key items organized within six qual-
ity domains: domain 1 = “Scope and purpose” (items 1‐3); 
domain 2 = “Stakeholder involvement” (items 4‐6); domain 
3 = “Rigor of development” (items 7‐14); domain 4 = “Clarity 
of presentation” (items 15‐17); domain 5 = “Applicability” 
(items 18‐21); and domain 6 = “Editorial independence”(items 
22‐23); domains are then followed by two additional items 
(“Overall Assessment”) to assess “the rating of the overall 
quality of the guideline and whether the guideline would be 
recommended for use in practice”.14 A comprehensive descrip-
tion of all AGREE II domains and items is reported in Table 1.
2.3 | Guidelines evaluation
According to AGREE recommendation, four independent ap-
praisers (VR, LU, SC, and RC) with 5‐8 years’ experience 
in head and neck diagnostic imaging and the field‐related re-
search performed the evaluation, in order to increase the relia-
bility of the assessment. Prior to the evaluation, all appraisers 
had performed the online training tool, freely available on 
the AGREE platform (www.agreetrust.org). For each item, a 
score from 1 to 7 was rated. Score 1 (strongly disagree) was 
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given when there was no relevant information concerning 
the item, the concept was poorly reported or criteria were not 
met; scores from 2 to 6 were assigned when the reporting of 
the AGREE II item did not meet the full criteria or considera-
tions. Score 7 (strongly agree) was assigned if the quality of 
reporting was exceptional and the full criteria were met. For 
each domain, final scores were calculated as the sum of indi-
vidual items scores, expressing the total as a percentage of the 
maximum possible score for that domain. The overall quality 
was evaluated using a threshold of 60% for the final score 
of each domain, with quality defined as “high” when 5 or 
more domains scored >60%, “average” when 3 or 4 domains 
scored >60%, and “low” when ≤2 domains scored >60%. In 
addition, overall scores, expressed as mean ± standard devia-
tion (SD) of both guidelines and domains, were calculated; 
domain scores were categorized as good (≥80%), acceptable 
(60%‐79.9%), low (40%‐59.9%), or very low (<40%).
2.4 | Statistical analysis
To assess the agreement among the four appraisers, intra-
class correlation coefficient (ICC) was used and classified as 
follows: poor (<0.20); fair (0.21‐0.40); moderate (0.41‐0.60); 
good (0.61‐0.80); and very good (0.81‐1.00), according to 
previous evidences.21,22
Data extraction, collection, and scoring were performed 
by an independent reviewer (AS) with 5 years of experi-
ence in statistical analysis of biomedical research data, using 
Microsoft Excel® 2016 (Microsoft Corporation, Redmond, 
WA, USA), while ICC analysis was performed using the 
Statistical Package for Social Science (SPSS) software (ver-
sion 24, IBM, Armonk, NY, USA).
3 |  RESULTS
After exhaustive literature search, 318 papers were retrieved 
of which three, published between 2012 and 2016, fulfilled 
all inclusion and exclusion criteria and were selected for 
the evaluation. Flow diagram of the selection process is il-
lustrated in Figure 1, and details of the selected papers are 
reported in Table 2. Of the selected guidelines, one scored 
“average” as overall quality, with three domains reaching 
percentage scores >60%, while the remaining two scored a 
T A B L E  1  Description of AGREE II domains and items (ref.14)
Domain 1. Scope and purpose Item 1: The overall objective(s) of the guideline is (are) specifically described
Item 2: The health question(s) covered by the guideline is (are) specifically described
Item 3: The population (patients, public, etc) to whom the guideline is meant to apply is specifically 
described
Domain 2. Stakeholder 
involvement
Item 4: The guideline development group includes individuals from all the relevant professional groups
Item 5: The views and preferences of the target population (patients, public, etc) have been sought
Item 6: The target users of the guideline are clearly defined
Domain 3. Rigor of development Item 7: Systematic methods were used to search for evidence
Item 8: The criteria for selecting the evidence are clearly described
Item 9: The strengths and limitations of the body of evidence are clearly described
Item 10: The methods for formulating the recommendations are clearly described
Item 11: The health benefits, side effects, and risks have been considered in formulating the 
recommendations
Item 12: There is an explicit link between the recommendations and the supporting evidence
Item 13: The guideline has been externally reviewed by experts prior to its publication
Item 14: A procedure for updating the guideline is provided
Domain 4. Clarity of presentation Item 15: The recommendations are specific and unambiguous
Item 16: The different options for management of the condition or health issue are clearly presented
Item 17: Key recommendations are easily identifiable
Domain 5. Applicability Item 18: The guideline describes facilitators and barriers to its application
Item 19: The guideline provides advice and/or tools on how the recommendations can be put into practice
Item 20: The potential resource implications of applying the recommendations have been considered
Item 21: The guideline presents monitoring and/or auditing criteria
Domain 6. Editorial independence Item 22: The views of the funding body have not influenced the content of the guideline
Item 23: Competing interests of guideline development group members have been recorded and addressed
212 |   ROMEO Et al.
F I G U R E  1  Flow diagram of 
guidelines selection
T A B L E  2  Guidelines selected for the evaluation
Title Country of origin Year Organization
American College of Radiology (ACR): Neck 
mass/adenopathy 
ACR Appropriateness Criteria6
USA Date of origin: 2009 Last 
review date: 2012
American College of Radiology 
(ACR)
Recommendations for cross‐sectional imaging in 
cancer management, Second edition—Head and 
neck cancer7
UK 2014 The Royal College of Radiology
Imaging in head and neck cancer: United 
Kingdom 
National Multidisciplinary Guidelines8
UK 2016 British Association of Endocrine 
and Thyroid Surgeons, British 
Association of Head and Neck 
Oncologists, British Association 
of Oral and Maxillofacial 
Surgeons, British Association of 
Otorhinolaryngology‐Head and 
Neck Surgery, British Association 
of Plastic, Reconstructive and 
Aesthetic Surgeons, The Royal 
College of Pathologists and The 
Royal College of Radiologists 
(Faculty of Clinical Oncology)
T A B L E  3  Summary of the average domains’ scores of HNC guidelines according to AGREE II
Domain ACR6 RCR7 UKNMG8 Total score mean SD
Overall 
domain score
1. Scope and purpose 66.67 52.78 59.72 59.72 6.94 Low
2. Stakeholder 
involvement
61.11 33.33 20.83 38.43 20.62 Very low
3. Rigor of development 56.77 21.35 23.44 33.85 19.87 Very low
4. Clarity of presentation 87.50 84.72 52.78 75.00 19.30 Acceptable
5. Applicability 32.29 58.33 29.17 39.93 16.01 Very low
6. Editorial independence 27.08 31.25 22.92 27.08 4.17 Very low
Total score mean 55.24 46.96 34.81
Overall quality Average Low Low
ACR, “American College of Radiology, ACR Appropriateness Criteria: neck mass/adenopathy”; RCR, “Recommendations for cross‐sectional imaging in cancer man-
agement, Second edition, Head and neck cancer” by the Royal College of Radiology; SD, standard deviation; UKNMG, “Imaging in head and neck cancer: United 
Kingdom National Multidisciplinary guidelines”; All values are expressed as percentages.
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“low” overall quality, with no more than one domain reaching 
a percentage score >60%. In particular, based on the average 
score of all domains, the guideline that reached the highest 
score (55.24%) was the “American College of Radiology, 
ACR Appropriateness Criteria: neck mass/adenopathy” 
(ACR),6 while the remaining two “Recommendations for 
cross‐sectional imaging in cancer management, Second 
edition—Head and neck cancer” by the Royal College of 
Radiology (RCR)7 and “Imaging in head and neck cancer: 
United Kingdom National Multidisciplinary Guidelines” 
(UKNMG)8 rated lower scores (34.81% and 46.96%, respec-
tively). Regarding overall domains’ scores, the highest (75%) 
was found for domain 4 “Clarity of presentation” while 
the lowest (27.1%) for domain 6 “Editorial independence.” 
The highest variability (SD 20.63%) was found in domain 2 
“Stakeholder involvement” and the lowest (4.17%) in domain 
6 “Editorial independence.” All average domains’ scores are 
reported in Table 3. In particular, domain 1 (Scope and pur-
pose) obtained scores of 66.67%, 52.78%, and 59.72% for 
ACR, RCR, and UKNMG guideline, respectively, with a 
mean score of 59.72% and a low variability (SD 6.94%). In 
domain 2 (Stakeholder involvement), the highest variability 
(SD 20.62%) was found among the three guidelines, due to 
discrepancies among the assigned scores; in particular, the 
highest score (61.11%) was assigned to ACR guideline, while 
the lowest (20.83%) to UKNMG, with an average score of 
38.43%. Regarding domain 3 (Rigor of development), the 
guideline with the highest score was that of the ACR with 
56.77%, while the lowest (21.35%) was scored by RCR 
guideline; due to this discrepancy, a SD of 19.87% was found 
for this domain with a mean score of 33.85%. In domain 
4 (Clarity of presentation), a score of 87.5%, 84.72%, and 
52.78% was calculated for ACR, RCR, and UKNMG guide-
lines, respectively, with a mean value of 75% ± 19.3%. RCR 
guideline reached the highest (58.33%) score for domain 5 
(Applicability), with lower scores assigned to ACR (32.29%) 
and UKNMG (29.17%), a final average score of 39.93% and 
a SD of 16%. The lowest variability (SD 4.17%) was found 
in domain 6, with a more homogeneous scoring of 27.08%, 
31.25%, and 22.92% for ACR, RCR, and UKNMG guide-
lines, respectively, and a mean percentage of 27.08%. ICC 
analysis showed a very good agreement among the four ap-
praisers; in detail, the ICC was 0.961 (CI 95%: 0.848‐0.994) 
for ACR guideline, 0.948 (CI 95%: 0.822‐0.992) for RCR 
guideline, and 0.932 (CI 95%: 0.729‐0.989) for UKNMG.
4 |  DISCUSSION
According to the AGREE II tool, we demonstrated a hetero-
geneous quality of existing guidelines on HNC imaging. One 
guideline reached an “average” level of quality, while the 
remaining two scored a “low” level of quality. Domains in 
which the highest percentage score was obtained were do-
main 1 “Scope and purpose” and domain 4 “Clarity of pres-
entation” since aims, target users, and key recommendations 
were clearly specified in all papers; this is in line with results 
obtained in previous evaluations,23,24 probably because these 
issues are essential for guideline drafting and therefore prop-
erly considered. On the basis of AGREE II items, the quality 
in these domains could be further improved specifying tim-
ing for follow‐up, stratifying recommendations on the basis 
of clinical features (eg, HPV status), or proposing alternative 
options for the use of different imaging techniques. In the 
remaining 4 domains, overall scores <40% were obtained. 
In detail, domain 2 “Stakeholder involvement” obtained an 
average score of 38.43%, mainly due to the lack of infor-
mation about target population views and preferences (do-
main 2), as also addressed by Lin and colleagues regarding 
the evaluation of guidelines for musculoskeletal pain.25 The 
noninvolvement of relevant professional figures other than 
radiologists in guideline's draft except for ACR guideline 
(in which neurologists, surgeons, and nuclear medicine spe-
cialists were also involved) could also explain this finding 
along with the highest variability (SD 20.62%) found among 
guidelines’ scores in this domain. Domain 3, “Rigor of de-
velopment,” scored an average percentage score of 33.85% 
since methods for searching or evaluating evidences were not 
always specified and no guideline authors’ team applied the 
Delphi or Glaser technique to achieve a mutual agreement 
among experts.26 However, it should be noted that certain 
items in this domain (eg, items 12 and 14) may not attract 
enough attention and, even if not reported, these methodolog-
ical aspects are often adequately performed.16,27,28 Regarding 
domain 5 “Applicability,” facilitators and barriers for guide-
lines’ application, resource implications, advice on how the 
recommendation can be put into practice as well as monitor 
or auditing criteria were not clearly specified in the guide-
lines under evaluation, resulting in the rather poor average 
score of 33.85%. Interestingly, this domain score was also 
found to be low in previous appraisals of clinical guidelines 
published in HNC,15,16,18 suggesting that the applicability of 
recommendations is underestimated during guidelines draft-
ing. Finally, as also occurred in previous evaluations,21,22,29 
domain 6 “Editorial Independence” was the most critically 
underperforming with an average score of 27.08% and the 
lowest variability (SD 4.17%), since neither an explicit state-
ment that the funding body interests have not influenced the 
final recommendations nor “no conflict of interest” statement 
were provided in two out of three guidelines. This is a crucial 
issue since the prevalence of conflicts of interest has been 
proved to be high among members of clinical practice guide-
line panels.30
With regard to the interobserver agreement among the 
four appraisers in this study, the ICC analysis showed a very 
good degree of concordance, thus confirming the suitability 
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of AGREE II tool. Its main strength lies in providing clear in-
structions for its application, enabling users to optimally per-
form the appraisal after completing the online training session.
According to the AGREE II instructions, it would have 
been possible to prioritize one domain over the others before 
beginning the appraisal, based on the evaluation of the im-
portance of the different domains and items in this context. 
Nevertheless, in agreement with the previous experiences21,22 
we did not prioritize a specific domain over the others as we 
consider all quality domains to equally contribute in deter-
mining the clinical implications of guidelines while evaluat-
ing different guidelines attributes.
Based on this evaluation, possible improvements in future 
guidelines on HNC imaging should be pursued giving par-
ticular attention to the Editorial independence, since guide-
lines are often developed with external funding or in some 
circumstances members of the development group may have 
competing interests introducing hence concealed bias. An 
acknowledgment section including an explicit statement in 
which the authors have declared if there are competing inter-
ests should be provided. Furthermore, robust, standardized 
methodologies for evidence research and evaluation (eg, using 
the Delphi or Glaser method) are warranted to strengthen 
the reliability of the process and should be reported in ded-
icated paragraphs. Strengths and limitations of the selected 
evidence should also be acknowledged and discussed as well 
as the methodology for guideline external review should be 
described. The inclusion of “multidisciplinary” groups, com-
posed by different professional stakeholders other than ra-
diologists (eg, radiation, medical, and surgical oncologists), 
would lead to a dramatic improvement in the HNC guidelines 
quality. Last but not least, issues such as the availability/costs 
of the recommended techniques should be considered in order 
to significantly improve guidelines quality and facilitate their 
translation into clinical practice. Specifically, it should be 
noted that the AGREE II tool does not accommodate any pa-
rameters related to dissimilarities among the various national 
healthcare systems as funding sources, patient cost‐sharing, 
availability and access to the cross‐sectional and hybrid im-
aging modalities, prevalence and socioeconomic burden of 
the disease linked with its cure rate and morbidity, and the 
reimbursement model either per item or per patient. Such im-
provements might be considered and incrementally included 
in future expansions and revisions of the AGREE tool.
Some limitations of the present study should be acknowl-
edged. First, the AGREE II tool rates the degree of meth-
odological rigor in guidelines, which is strongly related to 
but is not an index of the quality of content. Consequently, 
possible benefits of the recommendations on patients’ man-
agement could not be directly assessed. Second, consider-
able merit is given to the inclusion of specific statements 
related to possibly implicit issues, which may negatively af-
fect the final score of certain domains despite the elaborated 
methodological quality. Nevertheless, the AGREE II tool has 
been extensively validated and its limits are common among 
different appraisals tools.13 Finally, a low number of guide-
lines were included in this analysis; it should also be noted 
that since the selection included only guidelines published in 
English some guidelines might have been missed.
In conclusion, our AGREE II tool‐based analysis showed 
a heterogeneous quality of the existing guidelines on clinical 
HNC imaging. Issues raised from this appraisal should be 
considered when developing future guidelines in the field.
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